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Impairment of corneal nerves can result in the development of ocular surface diseases such as aqueous 
tear deficiency and neurotrophic keratopathy. This study investigates oral nicergoline, an α‐adrenoceptor 
antagonist shown to enhance endogenous secretion of nerve growth factor (NGF) by the lacrimal gland, 
as a potential therapy for these conditions. Five female spayed Beagle dogs received a 2‐week course of 
oral nicergoline (10 mg twice daily). Drug safety was evaluated with ophthalmic and physical 
examinations, blood pressure monitoring, bloodwork, and urinalysis. The effect of nicergoline on the 
ocular surface was assessed with corneal esthesiometry, Schirmer tear test‐1, and tear film breakup time. 
Drug effect on NGF levels was assessed by collecting tears and blood at baseline and completion of 
therapy using a bead‐based immunoassay and an enzyme‐linked immunosorbent assay. Although 
nicergoline was well tolerated in all dogs, it did not have a significant impact on corneal sensitivity, tear 
production, or tear stability. Of note, NGF was below the limit of quantification in all tear samples and was 
only detected in 8/20 serum samples with no significant difference between levels at baseline (189.4 ± 
145.1 pg/mL) and completion of therapy (149.4 ± 79.4 pg/mL). Further validation of NGF analytical 
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Abstract 
 
Impairment of corneal nerves can result in the development of ocular surface diseases such as aqueous 
tear deficiency and neurotrophic keratopathy. This study investigates oral nicergoline, an α-adrenoceptor 
antagonist shown to enhance endogenous secretion of nerve growth factor (NGF) by the lacrimal gland, 
as a potential therapy for these conditions. Five female spayed Beagle dogs received a 2-week course of 
oral nicergoline (10 mg twice daily). Drug safety was evaluated with ophthalmic and physical 
examinations, blood pressure monitoring, bloodwork and urinalysis. The effect of nicergoline on the 
ocular surface was assessed with corneal esthesiometry, Schirmer tear test-1 and tear film breakup time. 
Drug effect on NGF levels was assessed by collecting tears and blood at baseline and completion of 
therapy using a bead-based immunoassay and an enzyme-linked immunosorbent assay. Although 
nicergoline was well tolerated in all dogs, it did not have a significant impact on corneal sensitivity, tear 
production or tear stability. Of note, NGF was below the limit of quantification in all tear samples, and 
was only detected in 8/20 serum samples with no significant difference between levels at baseline (189.4 
± 145.1 pg/ml) and completion of therapy (149.4 ± 79.4 pg/ml). Further validation of NGF analytical 
assays is warranted before nicergoline is investigated in clinical patients. 
 
Keywords: Canine, Cochet-Bonnet, ELISA, Neurotrophic keratopathy, Nerve growth factor, 
Nicergoline  
Introduction 
Corneal nerves play a key role in maintaining the anatomical integrity and function of the ocular surface. 
They provide sensation for blinking and protection of the eye, mediate tear secretion, and supply 
epithelial and stromal cells with trophic factors important for corneal health.1,2 Impairment of corneal 
nerves is common in dogs, whether secondary to diseases such as diabetes mellitus and canine 
herpesvirus-1,3,4 or surgical procedures such as transscleral cyclophotocoagulation and ocular 
evisceration.5-7 Regardless of the underlying cause, corneal nerve injury can lead to neurotrophic 
keratopathy, a serious ocular disease characterized by persistent epithelial defects, reduced tear 
production and impaired wound healing.2,8 Corneal nerves take months to years to fully regenerate,2 and 
although therapeutic intervention can accelerate healing and restore the integrity of the ocular surface, 
no single therapy has proven effective in a reliable and cost-effective manner to date. Nicergoline, an α-
adrenoceptor antagonist described for cognitive disorders such as dementia,9 enhances endogenous 
secretion of nerve growth factor (NGF) by the lacrimal gland and could thereby provide sustained levels 
of NGF in the tear fluid of affected patients. 10,11 Studies on NGF have shown promising therapeutic 
outcomes in human patients with neurotrophic keratopathy or corneal wounds,11-15 as well as animal 
models with herpetic keratitis or dry eye; 16,17 however, topical NGF requires frequent administration to 
be effective, and is likely cost-prohibitive to most pet owners given the need to compound the drug at 
clinically relevant concentrations. The present study investigates the safety and usefulness of oral 
nicergoline as a potential alternative to topical NGF therapy in dogs. Following a nicergoline challenge 
per os, various systemic and ocular parameters were monitored and NGF levels in tears and plasma were 




Material and Methods 
Five female spayed Beagle dogs (1.5-2.0 years, 7.5-10.0 kg) were enrolled in the study and confirmed 
to be healthy based on physical and ophthalmic examinations. The sample size was based on a priori 
power calculation aimed at detecting a 50% change in lacrimal NGF levels between baseline and post- 
nicergoline therapy,11 assuming a power of 80% and a significance level of 0.05. The study was approved 
by the Institutional Animal Care and Use Committee of Iowa State University. Each dog received 10 mg 
of nicergoline [Сермион® (Sermion), Pfizer Inc., Russia] orally twice daily for 2 consecutive weeks. Of 
note, the drug is no longer produced by the manufacturer and was therefore obtained through an online 
pharmacy (nootropicspot.com) for the present study. Physical and ophthalmic examinations were 
performed daily throughout nicergoline administration. In addition, the following procedures were 
performed at baseline and at completion of the 2-week course: (i) complete blood count (CBC), serum 
biochemistry, and urinalysis to assess for systemic toxicity; (ii) indirect blood pressure monitoring 
(Doppler model 811-B, Parks Medical Electronics, Las Vegas, NV) due to the vasodilatory properties 
of nicergoline;9 (iii) corneal esthesiometry (Cochet-Bonnet aesthesiometer, Luneau Ophthalmologie, 
Chartres, France), Schirmer tear test-1 (STT-1; Eye Care Product Manufacturing, LLC, Tucson, AZ, 
USA) and tear film breakup time (TFBUT; Ful-Glo®, Akorn Inc., Buffalo Grove, IL, USA) to assess for 
drug effect on the ocular surface with each diagnostic test performed 10 min apart;18 and (iv) blood and 
tear collection to assess for drug effect on NGF levels, obtained prior to and 1h following the morning 
drug administration (Day 0 and Day 14). Blood was collected by jugular venipuncture, transferred into 
plain tubes, centrifuged at 1232g for 10 minutes, and the harvested serum was stored in 2-mL cryovials 
at -80°C. Tear fluid was collected in each eye with a Schirmer strip placed in the ventrolateral 
conjunctival fornix until 20-mm wetness was reached, followed by extraction of tears from the filter 
paper using one of two methods: (i) elution in phosphate-buffered saline (Gibco® PBS, pH 7.2, Thermo 
Fisher Scientific, Rockford, IL, USA) for samples collected on week 1, i.e. Schirmer strips cut into small 
pieces, placed in 400 µL of PBS for 3h at +4°C, followed by ultrasonic bath for 30min, centrifugation at 
3824g for 10min, and storage of the supernatant in 2-mL cryovials at -80°C; or (ii) centrifugation for 
samples collected on week 2, i.e. Schirmer strips placed in 0.2-mL vials that were previously punctured 
at their bottom with an 18-gauge needle, followed by centrifugation into 2-mL tubes at 3,884g for 2 
minutes and storage of tear fluid at -80°C. NGF levels were analyzed with either a bead-based 
immunoassay (NGF canine ProcartaPlexTM Simplex, InvitrogenTM, Waltham, MA, USA) for half of the 
samples (random selection), or an enzyme-linked immunosorbent assay (Human beta-NGF DuoSet 
ELISA, R&D)11 for the other set of samples. Statistical analysis was performed using SigmaPlot version 




Nicergoline was well tolerated in all dogs, with no noticeable changes in physical and ophthalmic 
examinations at any observable time point. Oral dosing with nicergoline did not affect systolic blood 
pressure, with measures obtained at baseline (128.1 ± 24.4 mmHg) being comparable to those at the end 
of nicergoline therapy (124.5 ± 13.0 mmHg; paired t-test, P = 0.637). Additionally, results from the 
complete blood count, serum biochemistry and urinalysis did not differ significantly between baseline 
and completion of therapy for all parameters (paired t-tests, P ≥ 0.057, Table 1), except for a statistically 
(but not clinically) significant decrease in total protein levels (5.94 ± 0.24 gm/dl vs. 5.7 ± 0.27 gm/dl, 
respectively; P < 0.001) and total calcium levels (10.70 ± 0.29 mg/dl vs. 10.56 ± 0.23 mg/dl, respectively; 
P = 0.025). No differences were noted between the right and left eyes for any ocular diagnostic test 
(paired t-tests, P ≥ 0.637), hence the average measurements from both eyes was used for statistical 
analysis. Mean (± standard deviation) values did not differ significantly between measurements obtained 
at baseline vs. completion of nicergoline therapy (paired t-tests, P ≥ 0.091) for corneal tactile sensation 
(2.4 ± 0.3 vs. 2.3 ± 0.3 cm, respectively, Figure 1A), STT-1 (17.4 ± 2.6 vs. 19.1 ± 0.9 mm/min, 
respectively, Figure 1B), and TFBUT (14.0 ± 3.4 vs. 17.3 ± 4.0 seconds, respectively, Figure 1C).  
Internal standards for NGF provided accurate standard curves for both ProcartaPlexTM assay (5 
parameters logistic regression, Figure 2A) and ELISA (second-degree polynomial regression, R2 = 
0.9996, Figure 2B). However, NGF levels were below the lower limit of quantification in all tear 
samples (3.9 and 31.3 pg/ml for ProcartaPlexTM and ELISA assays, respectively), and were only 
detectable with ELISA in 2/5 serum samples at baseline (86.7 and 292.0 pg/ml) and 6/15 serum samples 
collected after nicergoline administration (149.4 ± 79.4 pg/ml, 54.9-269.2 pg/ml). Nicergoline therapy 
did not significantly increase serum levels of NGF in dogs (paired t-test, P = 0.620). 
 
Discussion 
Nicergoline was well tolerated in dogs, although the drug did not affect the canine ocular parameters in 
a significant manner. Interestingly, tear production (STT-1) and tear stability (TFBUT) appeared to 
increase with nicergoline therapy, although the changes were not statistically significant and may be 
related to measurement noise given the low sample size and lack of control group. The latter represents 
a limitation of the study, and is important in establishing a causal relationship between drug 
administration and progression of clinical parameters, especially given the inherent variability of many 
ocular surface diagnostics in veterinary medicine.18 The inability to quantify NGF in canine tears is 
surprising, especially given the following measures undertaken in the present study: relatively high oral 
dosing (2-2.7 mg/kg/d vs. 0.5 mg/kg/d for behavioral disorders),20 two collection time points (to capture 
trough and peak concentrations), two different extraction methods (elution in PBS and centrifugation),21 
and two different analytical assays. Similarly, NGF was not detected in tear fluid of dogs using a 
multiplex bead-based immunoassay,22 albeit other chemokines/cytokines such as interleukin-8 and 
interferon-gamma were quantifiable at relatively high concentrations using the same analytical method. 
22,23 In contrast, Woo and colleagues detected high levels of NGF in canine tears (15.4 ± 4.6 ng/mL);24 
however, the ELISA test used in that study is no longer commercially available, and the assay guidelines 
discourage the use of this kit for samples rich in IgG (such as serum and tears) as it can lead to cross-
reactivity with NGF and falsely elevate absorbance readings (personal communication with 
manufacturer). Taken together, we believe that the apparent absence of lacrimal NGF in our canine 
subjects is related to inadequate analytical assays, and further tests validations are required before this 
promising growth factor is investigated in patients with neurotrophic keratopathy. Further, the adsorptive 
properties of Schirmer strips could theoretically impact NGF quantification, as shown for other 
proteins,25 hence other methods for tear collection could be considered in future studies (e.g. silicone 
tubing,24 microcapillary tubes,26 or ophthalmic sponges27-28). 
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Table 1. Results of complete blood count, serum biochemistry and urinalysis in 5 healthy female spayed 
Beagle dogs, assessed at baseline and following 2 weeks therapy with oral nicergoline (10 mg twice 
daily). WBC = white blood cells; RBC = red blood cells; MCV = mean corpuscular volume; MCH = 
mean corpuscular hemoglobin; MCHC = mean corpuscular hemoglobin concentration; RDW = red cell 
distribution width; MPV = mean platelet volume; BUN = blood urea nitrogen; Alk Phos = alkaline 
phosphatase; ALT = alanine aminotransferase; N/A = Not applicable. P-values depict results of paired 
t-tests, and are considered significant is P < 0.05 (in bold). 
 












WBC (x103/ul) 6 – 17 6.6 ± 0.9 6.6 ± 1.2 0.944 
RBC (x103/ul) 5.5 – 8.5 6.7 ± 0.5 6.4 ± 0.4 0.126 
Hemoglobin (gm/dl) 12 – 18 15.3 ± 0.9 14.6 ± 0.5 0.057 
Hematocrit (%) 37 – 55 45.6 ± 2.5 42.7 ± 3.0 0.061 
MCV (fl) 60 – 77 67.9 ± 2.3 68.3 ± 2.1 0.062 
MCH (pg) 19.5 – 30 22.8 ± 0.8 22.6 ± 0.8 0.330 
MCHC (gm/dl) 32 – 36 33.5 ± 0.2 33.2 ± 0.7 0.214 
RDW (%) 11.6 – 14.8 12.9 ± 0.3 13.2 ± 0.3 0.178 
Platelet (x103/ul) 200 – 500 306.6 ± 68.9 319.8 ± 54.3 0.564 
MPV (fl) 7 – 11 8.0 ± 1.0 7.7 ± 0.9 0.315 
Neutrophil (x103/ul) 3.0 – 11.4 4.0 ± 0.9 4.3 ± 1.2 0.661 
Lymphocyte (x103/ul) 1.0 – 4.8 2.0 ± 0.4 1.8 ± 0.3 0.414 
Monocyte (x103/ul) 0.15 – 1.35 0.3 ± 0.1 0.3 ± 0.1 0.427 
Eosinophil (x103/ul) 0 – 0.75 0.2 ± 0.1 0.2 ± 0.1 0.893 











Sodium (mEq/L) 141 – 151 146.4 ± 1.5 147.0 ± 0.7 0.573 
Potassium (mEq/L) 3.9 – 5.3 4.4 ± 0.3 4.1 ± 0.3 0.207 
Chloride (mEq/L) 112 – 121 116.4 ± 1.8 116.2 ± 0.8 0.861 
Bicarbonate (mEq/L) 19 – 25 22.4 ± 1.3 22.6 ± 1.1 0.847 
Calcium (mg/dl) 9.7 – 11.3 10.7 ± 0.3 10.6 ± 0.2 0.025 
Phosphorus (mg/dl) 3.2 – 6.0 3.7 ± 0.6 4.0 ± 0.3 0.092 
Magnesium (mg/dl) 1.7 – 2.5 1.9 ± 0.2 1.8 ± 0.2 0.275 
BUN (mg/dl) 10 – 30 15.8 ± 4.1 15.4 ± 1.8 0.803 
Creatinine (mg/dl) 0.5 – 1.5 0.7 ± 0.2 0.7 ± 0.2 0.704 
Glucose (mg/dl) 68 – 115 92 ± 11 92.6 ± 2.7 0.922 
Total protein (gm/dl) 5.2 – 7.1 5.94 ± 0.24 5.70 ± 0.27 < 0.001 
Albumin (gm/dl) 2.7 – 4.0 3.3 ± 0.2 3.3 ± 0.2 0.553 
Alk Phos (IU/L) 20 – 150 43.6 ± 17.9 41.4 ± 17.4 0.282 
ALT (IU/L) 19 – 80 35.8 ± 4.1 37.8 ± 6.3 0.230 
Total bilirubin (mg/dl) 0.1 – 0.6 0.1 ± 0.1 0.1 ± 0.1 0.258 
Cholesterol (mg/dl) 132 – 300 155.8 ± 28.7 150.6 ± 24.6 0.270 
Triglycerides (mg/dl) 24 – 115 43.4 ± 18.9 29.0 ± 4.9 0.182 














 Specific gravity 1.015 – 1.055 1.043 ± 0.012 1.051 ± 0.004 0.221 
Urine pH 5.5 – 6.5 6.3 ± 0.3 6.2 ± 0.3 0.374 
White cells (/hpf) < 3 0 0 1.000 
Red cells (/hpf) < 10 0 0 1.000 
Crystals 0 0 0 1.000 
Bacteria 0 0 0 1.000 
Epithelial cells None to rare Rare Rare N/A 
Glucose (mg/dl) Negative Negative Negative N/A 
Bilirubin Negative to 1+ Negative Negative N/A 
Ketones Negative Negative Negative N/A 
Proteins Negative Negative Negative N/A 
Figures 
 
Figure 1. Box-and-whisker plots depicting the results of corneal tactile sensation (A), Schirmer tear test-
1 (B) and tear film breakup time (C) in 5 healthy female Beagles dogs before (white box) and after (gray 
box) receiving a 2-week course of oral nicergoline (10 mg twice daily). Each plot represents the mean 
(dotted line), median (solid line), 2.5th percentile (lower whisker), 25th percentile (lower limit of box), 75th 





Figure 2. Standard curves (in blue) obtained with internal standards of nerve growth factor (NGF) with 
either bead-based immunoassay (A) or an enzyme-linked immunosorbent assay (B).  
 
 
